文献速递慢性肾脏病遗传性与小管间质肾病

如何估算常染色体显性多囊肾病患者的肾脏生长

How to Estimate Kidney Growth in Patients with Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2023-03-30

本文综述了常染色体显性多囊肾病(ADPKD)中估算肾脏体积生长速率的各种模型,指出目前对如何测量肾脏体积生长尚无共识,不同作者使用不同模型但被当作产生相似数值处理,可能导致错误的生长速率估算和预后判断;Mayo Clinic 分类是当前临床最广泛接受的预后模型,用于预测快速恶化患者和决定托伐普坦治疗。

要点

  • ADPKD 以囊肿发展致肾实质逐渐破坏和肾脏进行性生长为特征。
  • CT 或 MRI 测量的总肾脏体积(TKV)与未来 GFR 下降相关,是早期标志物。
  • 单次 TKV 测量估算的肾脏生长速率可为未来 GFR 下降的预后标志物,但测量方法尚无共识。

核心结论

  • ADPKD 中估算肾脏体积生长速率的模型多样且含义不同,被当作产生相似数值处理可能导致错误的生长速率估算和预后错误;Mayo Clinic 分类是当前临床最广泛接受的预后模型,用于预测快速恶化患者和决定托伐普坦治疗。

研究设计与样本

  • 综述,旨在呈现可用于估算 ADPKD 肾脏体积生长速率的模型以促进日常临床适用性。

主要发现

  • ADPKD 第一阶段估算 GFR 因肾小球超滤过增加而在肾实质减少时保持稳定。
  • CT 或 MRI 测量的 TKV 与未来 GFR 下降相关,已成为所有 ADPKD 患者应分析的早期标志物。
  • 近年指出单次 TKV 测量估算的肾脏生长速率可为未来 GFR 下降的明确预后标志物。
  • 对如何测量 ADPKD 肾脏体积生长尚无共识,各作者使用不同模型,含义不同但被当作产生相似数值处理,可能导致错误的生长速率估算和预后错误。

关键数值与推荐

  • Mayo Clinic 分类是当前临床实践中最广泛接受的预后模型,用于预测快速恶化患者和决定哪些患者应接受托伐普坦治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) is a disease characterized by a progressive kidney growth due to the development of cysts that lead to gradual destruction of the surrounding parenchyma. In the first stage, the estimated GFR will remain stable despite the reduction of the renal parenchyma because of an increase in glomerular hyperfiltration. The total kidney volume (TKV) measured with computed tomography or magnetic resonance imaging is related to the future GFR decline. Thus, TKV has become an early marker to be analyzed in all patients with ADPKD. In addition, in recent years, it has been pointed out that kidney growth rate estimated with a single TKV measurement can be a clear prognostic marker for future glomerular filtration decline. However, there is no consensus on how to measure kidney volume growth in ADPKD, so each author has used different models that, not having the same meaning, have been handled as if they produced similar values. This may lead to erroneous estimates of kidney growth rate with the consequent prognostic error. The Mayo Clinic classification is now the most widely accepted prognostic model in clinical practice to predict patients who will deteriorate faster and to decide what patients should be treated with tolvaptan. However, some aspects of this model have not been discussed in depth. Our aim in this review was to present the models that can be used to estimate kidney volume growth rate in ADPKD, to facilitate their applicability in daily clinical practice.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Borrego Utiel FJ, Espinosa Hernández M. How to Estimate Kidney Growth in Patients with Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2023. PMID: 36995133. doi:10.1681/ASN.0000000000000130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。